Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review

By sjmartinez • September 21, 2023

Garon EB, Visseren-Grul C, Rizzo MT, Puri T, Chenji S, Reck M. Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review. Front Oncol. 2023 Sep 4;13:1247879. doi: 10.3389/fonc.2023.1247879. PMID: 37731641; PMCID: PMC10507469.

Tags: antiangiogenic therapy, docetaxel, Hematology/Oncology, immune checkpoint inhibitors, Non-small cell lung cancer, Publications, ramucirumab

Early cellular events of osteomucosal healing in the tooth extraction socket

Kim S, Song M, Williams D, Du W, Cho I, Bae E, Kim J, Goswami A, Shin KH, Park NH, Kim RH. Early cellular events[...]

A treatment-impact model of alectinib for the prediction of recurrence and associated costs in treating resectable ALK+ non-small cell lung cancer

Cummings AL, Sussell J, Rosettie KL, Moustaid FE, Ogale S, Ngiam C, Jovanoski N, Arnold M, Lee JM. A treatment-impact model of alectinib for the[...]

A novel application of LC-MS/MS accurately quantifies the labile redox pools of cellular coenzymes Q9 and Q10

Jain A, Li VW, Salem J, Reddy ST, Palaskas NJ, Meriwether D. A novel application of LC-MS/MS accurately quantifies the labile redox pools of cellular[...]